TECX
Tectonic Therapeutic, Inc. Health Care Biological Products, (No Diagnostic Substances) Russell 3000
$19.78Close
$370.6MMarket cap
$16.44 – $37.9352-week range
Nov 5, 2026Next report
Highlights
Cautions
- Not in an uptrend 2 of 8 trend conditions
- Lagging the market RS 17 · weaker than 83% of stocks over 12 months
- Far from its high 48% below its 52-week high
- Distribution down-day volume 2.2× up-day volume over 50 sessions
- Results soon Nov 5, 2026, in 4 days
Price
Filing Results Screen pick 52-week high and low Adjusted prices
Key figures
Off 12-month high
48%
1wk
down 1.4%
price change
1mo
down 15.1%
price change
12-month return
up 12%
market up 11% ·
its own down 5%
F-score
—
— Not assessed
Altman Z
—
Unknown
P/E
—
price / earnings
PEG
—
P/E / EPS growth
P/B
1.5×
price / book
Earnings yield
down 71.9%
EBIT / enterprise value
Cheaper than
—
of the market · not assessed
Revenue growth
—
year on year
EPS growth
—
latest quarter
Sales growth
—
latest quarter
ROE
down 37822%
return on equity
Free cash margin
—
-$60.3M FCF
D/E
—
long-term debt / equity
Net debt / EBITDA
—
Interest cover
—EBIT / interest
Trade setup
ATR%
6.3%
$1.24 a day · 2×ATR $17.31
RS
17 / 99
vs the universe
Trend
2 / 8
trend template
Relative volume
0.7×
vs 50-day average
Up/down volume
0.46
50 sessions
Implied move
—
no option chain · report Nov 5, 2026
Trend template · 2 of 8
- 150-day average above the 200-day: passes
- 200-day average rising for a month: passes
Screen verdict
Did not qualify for any screen.
Warning signs
- Shareholders diluted The share count rose 26.1% over the year, from 15m to 19m shares. Each existing share owns a smaller fraction of the company than it did a year ago.
Last reported
Aug 6, 2026
Last shock
Aug 31, 2026-16% in one session3.4× volumeno filing matched-34% since
Financials
- Cash
- Long-term debt
| FY2020Dec 31, 2020 | FY2021Dec 31, 2021 | FY2022Dec 31, 2022 | FY2023Dec 31, 2023 | FY2024Dec 31, 2024 | FY2025Dec 31, 2025 | |
|---|---|---|---|---|---|---|
| Operating income | -$120.2M | -$118.8M | -$105.4M | -$44.6M | -$58.0M | -$84.0M |
| Net income | -$119.7M | -$119.1M | -$105.9M | -$42.8B | -$58.0B | -$74.2B |
| Earnings per share | — | -$2,779.81 | -$2.42 | -$33,758.45 | -$6,829.31 | -$4,046.98 |
| Free cash flow | -$100.0M | -$100.5M | -$97.5M | -$41.0M | -$59.2M | -$60.3M |
| Cash | $259.7M | $189.6M | $92.6M | $28.8M | $141.2M | $253.8M |
| Long-term debt | — | $15.0M | $15.0M | $0 | — | — |
| Shareholders' equity | $254.3M | $169.5M | -$45.7M | -$84.6M | $140.8M | $251.3M |
| Shares outstanding | 43.65m | 43.65m | 43.92m | 1.41m | 14.86m | 18.74m |
Filings
| Filed | Report | Period to | Lag |
|---|---|---|---|
| Aug 6, 2026 | Quarterly ↗ | Jun 30, 2026 | 37d |
| May 7, 2026 | Quarterly ↗ | Mar 31, 2026 | 37d |
| Feb 26, 2026 | Annual ↗ | Dec 31, 2025 | 57d |
| Nov 6, 2025 | Quarterly ↗ | Sep 30, 2025 | 37d |
| Aug 7, 2025 | Quarterly ↗ | Jun 30, 2025 | 38d |
| May 8, 2025 | Quarterly ↗ | Mar 31, 2025 | 38d |
| Mar 20, 2025 | Annual ↗ | Dec 31, 2024 | 79d |
| Nov 12, 2024 | Quarterly ↗ | Sep 30, 2024 | 43d |
| Aug 14, 2024 | Quarterly ↗ | Jun 30, 2024 | 45d |
| May 9, 2024 | Quarterly ↗ | Mar 31, 2024 | 39d |
| Mar 14, 2024 | Annual ↗ | Dec 31, 2023 | 74d |
| Nov 9, 2023 | Quarterly ↗ | Sep 30, 2023 | 40d |
Current reports
| Filed | Disclosed |
|---|---|
| Sep 29, 2026 | Other events ↗ |
| Aug 6, 2026 | Results ↗ |
| Jun 10, 2026 | Shareholder vote · Other events ↗ |
| May 7, 2026 | Results ↗ |
| Apr 23, 2026 | Director or officer change · Regulation FD ↗ |
| Feb 26, 2026 | Results ↗ |
| Feb 24, 2026 | Director or officer change · Regulation FD ↗ |
| Nov 6, 2025 | Results ↗ |
| Oct 30, 2025 | Other events ↗ |
| Aug 7, 2025 | Results · Regulation FD ↗ |
| Jun 6, 2025 | Shareholder vote ↗ |
| May 19, 2025 | Other events ↗ |